學術兼職: 1. 私立紐約大學兼職副教授 2. 英國南漢普頓大學Southampton Statistical Sciences Research Institute, Associate. 3. Steering Committee, Multi-purpose Prevention Technologies Initiatives 4. Guideline Development Group, 世衛組織Sexual, Reproductive Health and Rights 5. 中國性病艾滋病防治協會常務委員 6. Frontiers in Immunology, Associate Editor 7. Frontiers in Microbiology, Review Editor
|
|
吳稚偉1982年本科畢業于南京大學;1991年獲英國愛丁堡大學博士學位;1990-1997年在美國私立紐約大學接受博士後訓練,1997-2006分别在洛克菲勒大學和賓夕法尼亞大學Leon Levy研究中心擔任助理教授和高級研究員職位。2006年應南京大學聘請,負責組建公共健康醫學中心。現任南京大學教授,博導,公共健康醫學中心主任,南京大學生命分析化學國家重點實驗室副主任。兼任私立紐約大學客座副教授(adjunct associate professor)和英國南漢普頓大學社會科學和生物統計學院Associate Member。 吳稚偉長期從事病毒感染和免疫學,疫苗和抗病毒藥物的研究和開發。主要的研究興趣有如下幾方面:(1)細胞外囊泡(sEV)對病毒的病理、宿主抗病毒免疫調控和病毒傳播的影響及作用的分子機制;利用胞外囊泡作為病毒感染治療性藥物的靶向遞送載體(2)RNA病毒與宿主細胞的相互作用,對宿主免疫系統幹擾、調控以及對病毒緻病分子機制的研究(3)利用納米抗體誘導和發現的技術平台,研究和開發高效抑制病毒複制的治療用納米單克隆抗體,并通過人源化、納米抗體工程化構建高生物學效價、内體長效納米抗體,并研發不同的納米抗體藥物遞送途徑(4)利用納米抗體的高親和力特點,研制用于特異性、高靈敏納米抗體快速免疫診斷試劑,特别是用于臨場檢測的POCT裝置。 吳稚偉曾擔任艾滋病疫苗基礎研究專項(973項目)課題負責人,國家十一五,十二五和十三五傳染病重大專項負責人,承擔對艾滋病生物預防,疫苗和高緻病性病毒感染(如SFTSV, EV71, SARS-CoV2,MERS-CoV, EBOV和HIV-1等)的治療性抗體和診斷技術研究。吳稚偉同時高度關注公共衛生及疾病幹預, 在若幹國際組織中任職,如美國MPTi Steering Committee委員, 在世界衛生組織(WHO) Microbicides Regional Temporary Advisory 和WHO Guidelines Development Group (voting member)擔任專家委員, 以及擔任Frontiers in Immunology副主編,Frontiers in Pharmacology評審編輯(Review Editor)。 |
Yuxuan Fu, Li Zhang, Fang Zhang, Ting Tang, Chunhong Feng, Yu Jin, Zhiwei Wu*.Exosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection. PloS Pathogen (2017). 13(9):e1006611. https://doi.org/10.1371/journal. ppat. 1006611. Peixin Song, Nan Zheng, Yong Liu, Chen Tian, Xilin Wu, Xiaohua Ma, Deyan Chen, Xue Zou, Guiyang Wang, Huanru Wang, Yongyang Zhang, Sufang Lu, Chao Wu, Zhiwei Wu*. Deficient humoral response and disrupted B cell immunity are associated with fatal SFTSV infection. Nature Communications(2018) 9:3328/DOI: 10.1038/s41467-018-05746-9. Xilin Wu, Yanlei Li,Xiaohua Ma, Linjing Zhu, Bilian Huang, Nan Zheng, Shijie Xu, Waqas Nawaz, Zhiwei Wu*. Development of a potent neutralizing nanobody as therapeutics against SFTSV infection. JCI Insight. 2020; 5(13):e136855. https://doi.org/10.1172/jci.insight. 136855. Xue Zou, Meng Yuan, Yutong Zhang, Nan Zheng*and Zhiwei Wu*. Extracellular vesicles containing host restriction factor IFITM3 inhibited Zika virus infection of fetuses in pregnant mice through trans-placenta delivery. Molecular Therapy Vol. 29 No.1 Jan. 2021. pp 1-15. Waqas Nawaz, Shijie Xu, Yanlei Li, Bilian Huang, Xilin Wu*, Zhiwei Wu*. NanoTech and Immunoengineering: How nanotech can boost CAR-T therapy. Acta Biomaterialia 109 (2020) 21-36. Frederik J. Verweij, Leonora Balaj, Chantal Boulanger, David RF Carter, Ewaldus B Compeer, Gisela D’Angelo G, Samir El Andaloussi, Jacky G. Goetz, Julia Groß, Vincent Hyenne, Eva-Maria Krämer-Albers A, Charles Lai, Xavier Loyer, Alex Marki, Stefan Momma, Esther Nolte ‘t Hoen, Michiel D Pegtel, Hector Peinado, Graça Raposo, Kirsi Rilla, Hidetoshi Tahara, Clotilde Théry, Martin Van Royen, Roosmarijn Vandenbroecke, Ann Wehman, Kenneth Witwer, Zhiwei Wu, Richard Wubbolts, Guillaume van Niel. The power of imaging to understand EV biology in vivo. Nature Methods (2021). https://doi.org/10.1038/s41592-021-01206-3. Waqas Nawaz, Bilian Huang, Shijie Xu,Yanlei Li, Linjing Zhu, Hu Yiqiao, Zhiwei Wu*, Xilin Wu*. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer Journal (2021) 11:119; https://doi.org/10.1038/s41408-021-00508-1. Shijie Xu, Na Jiang, Waqas Nawaz, Bingxin Liu, Fang Zhang, Ye Liu, Xilin Wu* and Zhiwei Wu*. Infection of humanized mice with a novel phlebovirus presented pathogenic features of sever fever with thrombocytopenia syndrome. PloS Pathog (2021) 17(5): e1009587. https:// doi.org/10.1371/journal.ppat.1009587. Li Zhang, Yuxuan Fu, Rui Zhang, Yajie Guan, Na Jiang, Nan Zheng*, Zhiwei Wu*. Nonstructural protein NSs hampers cellular antiviral response through LSm14A during Severe Fever with Thrombocytopenia Syndrome Virus Infection. J Immunol.2021, 207: 1-12. Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Yalan Liu, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Zhiwei Wu*.Potent bispecific nanobody provides in vivo protection against SARS-CoV-2 via intranasal administration. Cell Reports (2021)(In press).
|